产品
编 号：F154314
分子式：C23H23F3N2O4
分子量：448.43
分子式：C23H23F3N2O4
分子量：448.43
产品类型
规格
价格
是否有货
10mM*1mL in DMSO
询价
询价
1mg
询价
询价
5mg
询价
询价
10mg
询价
询价
50mg
询价
询价
结构图
CAS No: 1415716-58-3
产品详情
生物活性：
TG6-10-1 is an EP2 antagonist, shows low-nanomolar antagonist activity against only EP2, >300-fold selectivity over human EP3, EP4, and IP receptors, 100-fold selectivity over EP1 receptors.
体内研究：
TG6-10-1 (5 mg/kg; i.p.; 4-30 hours) improves survival, accelerates recovery of lost weight, and improves functional recovery following status epilepticus (SE) .Animal Model:C57BL/6 mice (pilocarpine-induced SE)
Dosage:5 mg/kg
Administration:Intraperitoneal injection; 4, 21, 30 hours
Result:A significant increase in survival and accelerating the recovery of lost weight in post-SE mice.
体外研究：
TG6-10-1 robustly blocks prostaglandin E2 (PGE2) (10 μM)-induced cAMP accumulation in a concentration-dependent manner in SH-SY5Y cells.
TG6-10-1 is an EP2 antagonist, shows low-nanomolar antagonist activity against only EP2, >300-fold selectivity over human EP3, EP4, and IP receptors, 100-fold selectivity over EP1 receptors.
体内研究：
TG6-10-1 (5 mg/kg; i.p.; 4-30 hours) improves survival, accelerates recovery of lost weight, and improves functional recovery following status epilepticus (SE) .Animal Model:C57BL/6 mice (pilocarpine-induced SE)
Dosage:5 mg/kg
Administration:Intraperitoneal injection; 4, 21, 30 hours
Result:A significant increase in survival and accelerating the recovery of lost weight in post-SE mice.
体外研究：
TG6-10-1 robustly blocks prostaglandin E2 (PGE2) (10 μM)-induced cAMP accumulation in a concentration-dependent manner in SH-SY5Y cells.
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备